C. Höss

发表

Gender differences in myocardial blood flow dynamics: lipid profile and hemodynamic effects.

M. Schwaiger, F. Dayanikli, I. Matsunari, 1999, Journal of the American College of Cardiology.

Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).

M. Rezai, P. Fasching, H. Tesch, 2013, European journal of cancer.

Prospective multi-center study for quantification of chemotherapies and CTX-related direct medication costs avoided by use of biomarkers uPA and PAI-1 in primary breast cancer.

M. Kiechle, V. Jacobs, B. Rack, 2013, Breast.

Abstract P1-11-03: Pathological Complete Response after Neoadjuvant Chemotherapy + Trastuzumab Treatment Predicts Survival and Detects a Patient Subgroup at High Need for Improvement of Anti-HER2 Therapy. Three Year Median Follow-Up Data of the TECHNO Trial

P. Fasching, T. Kühn, R. Kreienberg, 2010 .

Histopathologic features of ovarian borderline tumors are not predictive of clinical outcome.

H. Höfler, S. Hauptmann, M. Kiechle, 2012, Gynecologic oncology.

[Local tumor control and cosmetic outcome following breast-conserving surgery and radiation up to a total dose of 56 Gy without boost in breast cancer].

H. Feldmann, P. Lukas, M. Molls, 2001, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

Variations of steroid hormone metabolites in serum and urine in polycystic ovary syndrome after nafarelin stimulation: evidence for an altered corticoid excretion.

R. Kimmig, T. Strowitzki, P. Luppa, 1995, The Journal of clinical endocrinology and metabolism.

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

P. Fasching, T. Kühn, R. Kreienberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer--a prospective multicenter phase II trial (PRIMOVAR).

C. Leutner, W. Kuhn, O. Ortmann, 2009, Oncology reports.

Bone metabolism during the perimenopausal transition: a prospective study.

K. Ulm, P. Luppa, T. Treumann, 2002, Maturitas.

Ten-year data on 138 patients with endometrial carcinoma and postoperative vaginal brachytherapy alone: no need for external-beam radiotherapy in low and intermediate risk patients.

R. Thamm, M. Molls, B. Röper, 2007, Gynecologic oncology.

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.

M. Rezai, T. Fehm, T. Kühn, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.